KalVista Pharmaceuticals, Inc. (KALV) Stock Score, Valuation & Financial Research

KalVista Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for KALV

KalVista Pharmaceuticals, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 27.00. These figures are a research snapshot, not a buy or sell recommendation.

What KalVista Pharmaceuticals, Inc. does

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

KalVista Pharmaceuticals is a biopharmaceutical company that generates revenue through the commercialization of its proprietary oral therapies for rare diseases. The company focuses on the discovery, development, and global marketing of small molecule protease inhibitors, specifically targeting plasma kallikrein to treat conditions like hereditary angioedema (HAE).

Products and services

  • EKTERLY (sebetralstat) is an oral, on-demand therapy approved for the treatment of acute attacks of hereditary angioedema (HAE) in patients aged 12 years and older.

Brands and product families

  • EKTERLY — Oral on-demand therapy for the treatment of acute attacks of HAE. Source

Customer types

Patients with hereditary angioedema (HAE).

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its drug candidates and commercial products. Source

Competitors and product-market comparisons

  • Shire — Developer of plasma kallikrein monoclonal antibody (SHP643) for HAE. Source
  • Biocryst Pharmaceuticals — Developer of oral plasma kallikrein inhibitor (BCX7353) for HAE. Source

Business strengths to evaluate

  • Proprietary oral therapy platform for rare diseases Source

Business risks and research considerations

  • Dependence on third-party manufacturers for product supply Source
  • Intense competition in the pharmaceutical industry Source

Sources: Company research source · Shire

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

KALV financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 27.00
Market capitalization:
1.44B (currency not supplied)
Revenue:
USD 115.91M
Net income:
USD -138.44M
Free cash flow:
USD -83.33M
Cash:
USD 229.34M
Total debt:
USD 284.21M
EPS:
USD -3.23

What stands out

  • Reported year-over-year revenue growth is +57.4%.
  • Free cash flow is USD -83.33M, negative for the stored period.
  • The balance sheet shows USD 229.34M of cash versus USD 284.21M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -71.9% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -119.4% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Debt exceeds cash by USD 54.87M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for KALV

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • Can KALV sustain its current revenue growth while also converting that growth into durable profit and free cash flow?
  • How long can KALV fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does KALV's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for KALV to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of KALV's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research KALV

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.